The rise and fall of beta-agonists in the treatment of ARDS

Critical Care, 04/10/2012

The ALTA trial was terminated on the grounds of futility after it became clear that salbutamol did not affect ventilator–free days. The BALTI–2 trial was terminated for similar reasons alongside concerns about safety and tolerability. Together these findings suggest that the routine administration of β–agonists as a treatment for acute respiratory distress syndrome (ARDS) should be avoided.

Print Article Summary

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List